{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:27:21Z","timestamp":1784564841211,"version":"3.55.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.beem.2023.101834","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T12:30:04Z","timestamp":1697805004000},"page":"101834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tumor-induced osteomalacia: An overview"],"prefix":"10.1016","volume":"38","author":[{"given":"Swati Sachin","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravikumar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","article-title":"Tumor-induced Osteomalacia","volume":"108","author":"Florenzano","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"10.1016\/j.beem.2023.101834_bib2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1507\/endocrj.EJ16-0587","article-title":"The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases","volume":"64","author":"Feng","year":"2017","journal-title":"Endocr J"},{"issue":"9","key":"10.1016\/j.beem.2023.101834_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.beem.2023.101834_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00223-021-00843-2","article-title":"Epidemiology of tumor-induced Osteomalacia in Denmark","volume":"109","author":"Abrahamsen","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2023.101834_bib5","first-page":"33","article-title":"Osteomalacia with Looser\u2019s nodes (Milkman\u2019s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years","volume":"16","author":"McCance","year":"1947","journal-title":"Q J Med"},{"issue":"3","key":"10.1016\/j.beem.2023.101834_bib6","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2023.101834_bib7","first-page":"554","article-title":"Rickets following bone tumor","volume":"14","author":"Prader","year":"1959","journal-title":"Helv Paediatr Acta"},{"issue":"11","key":"10.1016\/j.beem.2023.101834_bib8","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.beem.2023.101834_bib9","doi-asserted-by":"crossref","first-page":"e3428","DOI":"10.1210\/clinem\/dgac253","article-title":"Tumor-induced Osteomalacia: a systematic review and individual patient's data analysis","volume":"107","author":"Rendina","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2023.101834_bib10","doi-asserted-by":"crossref","first-page":"F785","DOI":"10.1152\/ajprenal.00250.2021","article-title":"Fibroblast growth factor 23 leads to endolysosomal routing of the renal phosphate cotransporters NaPi-IIa and NaPi-IIc in vivo","volume":"321","author":"K\u00fcng","year":"2021","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"10.1016\/j.beem.2023.101834_bib11","doi-asserted-by":"crossref","first-page":"F371","DOI":"10.1152\/ajprenal.00740.2010","article-title":"Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4","volume":"301","author":"Gattineni","year":"2011","journal-title":"Am J Physiol Ren Physiol"},{"issue":"4","key":"10.1016\/j.beem.2023.101834_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.4465","article-title":"Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour","volume":"235","author":"Lee","year":"2015","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.beem.2023.101834_bib13","first-page":"1335","article-title":"Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors","volume":"29","author":"Lee","year":"2016","journal-title":"Mod Pathol J U S Can Acad Pathol, Inc"},{"key":"10.1016\/j.beem.2023.101834_bib14","article-title":"Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets\/osteomalacia (TIO)","volume":"10","author":"Kinoshita","year":"2018","journal-title":"Bone Rep"},{"issue":"8","key":"10.1016\/j.beem.2023.101834_bib15","first-page":"2551","article-title":"Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling","volume":"25","author":"Martin","year":"2011","journal-title":"FASEB J Publ Fed Am Soc Exp Biol"},{"issue":"8","key":"10.1016\/j.beem.2023.101834_bib16","article-title":"Infigratinib reduces fibroblast growth factor 23 (FGF23) and increases blood phosphate in tumor-induced Osteomalacia","volume":"6","author":"Hartley","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.beem.2023.101834_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1210\/endrev\/bnac026","article-title":"Tumor-induced Osteomalacia: a comprehensive review","volume":"44","author":"Minisola","year":"2023","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib18","first-page":"69","article-title":"Phosphatonins: from discovery to therapeutics","volume":"29","author":"Kritmetapak","year":"2023","journal-title":"Endocr Pr J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5414\/CN108596","article-title":"Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23","volume":"85","author":"Bansal","year":"2016","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature","volume":"28","author":"Folpe","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"7746","key":"10.1016\/j.beem.2023.101834_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(72)92844-9","article-title":"Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia","volume":"299","author":"Evans","year":"1972","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.beem.2023.101834_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJM197204062861402","article-title":"Tertiary\u201d hyperparathyroidism and apparent \u201ccure\u201d of vitamin-D-resistant rickets after removal of an ossifying mesenchymal tumor of the pharynx","volume":"286","author":"Olefsky","year":"1972","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beem.2023.101834_bib23","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q","article-title":"Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets","volume":"59","author":"Weidner","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2023.101834_bib24","series-title":"Phosphaturic Mesenchymal Tumour","first-page":"211","author":"Folpe","year":"2013"},{"issue":"4","key":"10.1016\/j.beem.2023.101834_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.semdp.2019.07.002","article-title":"Phosphaturic mesenchymal tumors: a review and update","volume":"36","author":"Folpe","year":"2019","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"10.1016\/j.beem.2023.101834_bib26","first-page":"189","article-title":"Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review","volume":"32","author":"Wu","year":"2019","journal-title":"Mod Pathol J U S Can Acad Pathol"},{"issue":"10","key":"10.1016\/j.beem.2023.101834_bib27","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/PAS.0000000000000890","article-title":"Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum","volume":"41","author":"Agaimy","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.beem.2023.101834_bib28","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-4453","article-title":"Two CAse Reports of FGF23-induced hypophosphatemia in childhood biliary atresia","volume":"138","author":"Wasserman","year":"2016","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.beem.2023.101834_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231728","article-title":"Tumour-induced osteomalacia due to an intra-abdominal mesenchymal tumour","volume":"12","author":"Krishnappa","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.beem.2023.101834_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00223-022-01005-8","article-title":"Tumor-induced Osteomalacia: a systematic clinical review of 895 cases","volume":"111","author":"Bosman","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2023.101834_bib31","unstructured":"Kumar S., Shah R., Patil V. et al. Tumor-induced rickets-osteomalacia: an enigma. Journal of pediatric endocrinology & metabolism: JPEM, \/j\/jpem.ahead-of-print\/jpem-2020\u20130079\/jpem-2020\u20130079.xml."},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3892\/ol.2014.2081","article-title":"Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases","volume":"8","author":"Morimoto","year":"2014","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.beem.2023.101834_bib33","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1530\/EC-19-0341","article-title":"Tumor induced osteomalacia in head and neck region: single center experience and systematic review","volume":"8","author":"Shah","year":"2019","journal-title":"Endocr Connect"},{"issue":"7929","key":"10.1016\/j.beem.2023.101834_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphate concentration","volume":"2","author":"Walton","year":"1975","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beem.2023.101834_bib35","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","article-title":"Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia","volume":"91","author":"Imel","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101834_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.beem.2023.101834_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S2213-8587(19)30426-7","article-title":"Approach to patients with hypophosphataemia","volume":"8","author":"Florenzano","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2023.101834_bib38","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1210\/clinem\/dgab885","article-title":"Serum metabolomics reveals dysregulation and diagnostic potential of oxylipins in tumor-induced osteomalacia","volume":"107","author":"Gong","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2023.101834_bib39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.beem.2023.101834_bib40","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","article-title":"Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in localization of tumor causing oncogenic osteomalacia","volume":"40","author":"Agrawal","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.beem.2023.101834_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2014.04.016","article-title":"68Ga DOTA-TATE PET\/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT\/CT","volume":"64","author":"Breer","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.beem.2023.101834_bib42","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","article-title":"68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia","volume":"101","author":"El-Maouche","year":"2016","journal-title":"J Clin Endocrinol Metab 2016"},{"issue":"4","key":"10.1016\/j.beem.2023.101834_bib43","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s00330-020-07342-2","article-title":"Diagnostic efficiency of (68)Ga-DOTANOC PET\/CT in patients with suspected tumour-induced osteomalacia","volume":"31","author":"He","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.beem.2023.101834_bib44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","article-title":"Localisation of mesenchymal tumours by somatostatin receptor imaging","volume":"359","author":"Jan de Beur","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beem.2023.101834_bib45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MNM.0000000000001163","article-title":"Performance of 68Ga-DOTA-SST PET\/CT, octreoscan SPECT\/CT and 18F-FDG PET\/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis","volume":"41","author":"Jiang","year":"2020","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10010002","article-title":"Detection rate of culprit tumors causing osteomalacia using somatostatin receptor PET\/CT: systematic review and meta-analysis","volume":"10","author":"Meyer","year":"2019","journal-title":"Diagnostics"},{"issue":"10","key":"10.1016\/j.beem.2023.101834_bib47","doi-asserted-by":"crossref","first-page":"e4202","DOI":"10.1210\/clinem\/dgab258","article-title":"Utility of 18F-AlF- NOTA-octreotide PET\/CT in the localization of tumor-induced osteomalacia","volume":"106","author":"Long","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cen.12426","article-title":"Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET\/ CT vs somatostatin receptor-based functional scans: a series of nine patients","volume":"81","author":"Jadhav","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib49","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","article-title":"Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in localization of tumor causing oncogenic osteomalacia","volume":"40","author":"Agrawal","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.beem.2023.101834_bib50","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jbmr.1881","article-title":"Tumor localization and biochemical response to cure in tumor-induced osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.beem.2023.101834_bib51","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/RLU.0000000000003463","article-title":"Prognostic value of positive presurgical FDG PET\/CT in the evaluation of tumor-induced osteomalacia","volume":"46","author":"Wang","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib52","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.beem.2023.101834_bib53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clinimag.2019.04.007","article-title":"Tumor-induced osteomalacia \u2014current imaging modalities and a systematic approach for tumor localization","volume":"56","author":"Rayamajhi","year":"2019","journal-title":"Clin Imaging"},{"key":"10.1016\/j.beem.2023.101834_bib54","doi-asserted-by":"crossref","first-page":"08","DOI":"10.1259\/bjr.20160811","article-title":"Oncogenic osteomalacia: role of Ga-68 DOTANOC PET\/CT scan in identifying the culprit lesion and its management","volume":"90","author":"Singh","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.beem.2023.101834_bib55","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3349\/ymj.2017.58.5.981","article-title":"Localization of oncogenic osteomalacia by systemic venous sampling of fibroblast growth factor 23","volume":"58","author":"Lee","year":"2017","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.beem.2023.101834_bib56","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1210\/jc.2013-2528","article-title":"Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy","volume":"98","author":"Tarasova","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2023.101834_bib57","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/jbmr.4620","article-title":"Clinical challenges in diagnosis, tumor localization and treatment of tumor-induced osteomalacia: outcome of a retrospective surveillance","volume":"37","author":"Hidaka","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.beem.2023.101834_bib58","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jos.2020.07.006","article-title":"Surgical margin for phosphaturic mesenchymal tumors in soft tissues: an analysis of the radiological histopathological correlation","volume":"26","author":"Kobayashi","year":"2021","journal-title":"J Orthop Sci"},{"issue":"11","key":"10.1016\/j.beem.2023.101834_bib59","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/CM9.0000000000001448","article-title":"Consensus on clinical management of tumor-induced osteomalacia","volume":"134","author":"Jiang","year":"2021","journal-title":"Chin Med J"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-015-0496-3","article-title":"Surgical treatment of tumor- induced osteomalacia: a retrospective review of 40 cases with extremity tumors","volume":"16","author":"Sun","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"10.1016\/j.beem.2023.101834_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177835","article-title":"Total hip\/knee arthroplasty in the treatment of tumor-induced osteomalacia patients: more than 1 year follow-up","volume":"12","author":"Zhu","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib62","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bone.2006.07.027","article-title":"A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery","volume":"40","author":"Elston","year":"2007","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.beem.2023.101834_bib63","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature","volume":"27","author":"Jiang","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.beem.2023.101834_bib64","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00223-009-9275-1","article-title":"Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases","volume":"85","author":"Rendina","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2023.101834_bib65","article-title":"Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome","volume":"12","author":"Kumar","year":"2020","journal-title":"Bone Rep"},{"key":"10.1016\/j.beem.2023.101834_bib66","article-title":"High bone turnover and hyperparathyroidism after surgery for tumor-induced osteomalacia: a case series","volume":"15","author":"Kilbane","year":"2021","journal-title":"Bone Rep"},{"key":"10.1016\/j.beem.2023.101834_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.686135","article-title":"Prolonged hypophosphatemia and intensive care after curative surgery of tumor induced osteomalacia: a case report","volume":"12","author":"Ryh\u00e4nen","year":"2021","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.beem.2023.101834_bib68","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019090","article-title":"Clinical, histopathologic, subtype, and immunohistochemical analysis of jaw phosphaturic mesenchymal tumors","volume":"99","author":"Li","year":"2020","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.beem.2023.101834_bib69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/RLU.0000000000002458","article-title":"99mTc-HYNIC-TOC In the evaluation of recurrent tumor- induced osteomalacia","volume":"44","author":"Shi","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib70","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/wjnm.WJNM_92_18","article-title":"68)Ga-DOTATATE positron emission tomography\/computed tomography to detect the recurrence of phosphaturic mesenhcymal tumor-induced osteomalacia","volume":"19","author":"Bhalla","year":"2020","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.beem.2023.101834_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2023.101834_bib72","first-page":"231s","article-title":"Vitamin D resistant hypophosphataemic osteomalacia: treatment with 1alpha-hydroxyvitamin D3","volume":"7","author":"Peacock","year":"1977","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101834_bib73","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1359\/jbmr.070304","article-title":"Cinacalcet in the management of tumor-induced osteomalacia","volume":"22","author":"Geller","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"26","key":"10.1016\/j.beem.2023.101834_bib74","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","article-title":"Octreotide therapy for tumor- induced osteomalacia","volume":"345","author":"Seufert","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beem.2023.101834_bib75","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/jbmr.3162","article-title":"Octreotide is ineffective in treating tumor-induced osteomalacia: results of a short-term therapy","volume":"32","author":"Ovejero","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.beem.2023.101834_bib76","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.beem.2023.101834_bib77","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open- label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"14","key":"10.1016\/j.beem.2023.101834_bib78","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMc2020399","article-title":"Targeted FGFR blockade for the treatment of tumor-induced osteomalacia","volume":"383","author":"Hartley","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beem.2023.101834_bib79","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1210\/jc.2013-4515","article-title":"Radiofrequency ablation, an effective modality of treatment in tumor-induced osteomalacia: a case series of three patients","volume":"99","author":"Jadhav","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2023.101834_bib80","first-page":"81","article-title":"Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series","volume":"3","author":"Mishra","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.beem.2023.101834_bib81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/CH-200921","article-title":"Application of ultrasound-guided biopsy and percutaneous radiofrequency ablation in 2 cases with phosphaturic mesenchymal tumor and literature review","volume":"77","author":"Xian","year":"2021","journal-title":"Clin Hemorheol Microcirc"},{"issue":"9","key":"10.1016\/j.beem.2023.101834_bib82","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s00270-016-1350-1","article-title":"Ga-68 DOTATOC PET\/CT-guided biopsy and cryoablation with autoradiography of biopsy specimen for treatment of tumor-induced osteomalacia","volume":"39","author":"Maybody","year":"2016","journal-title":"Cardiovasc Interv Radiol"},{"issue":"11","key":"10.1016\/j.beem.2023.101834_bib83","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/jbmr.3219","article-title":"Multimodality image-guided cryoablation for inoperable tumor-induced osteomalacia","volume":"32","author":"Tella","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.beem.2023.101834_bib84","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1210\/jc.2012-1719","article-title":"Successful treatment of tumor-induced osteomalacia with CT-guided percutaneous ethanol and cryoablation","volume":"97","author":"Tutton","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2023.101834_bib85","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00256-016-2548-7","article-title":"Successful CT guided cryoablation of phosphaturic mesenchymal tumor in the soft tissues causing tumor-induced osteomalacia: a case report","volume":"46","author":"Cowan","year":"2017","journal-title":"Skelet Radiol"},{"issue":"11","key":"10.1016\/j.beem.2023.101834_bib86","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1210\/jc.2013-2528","article-title":"Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy","volume":"98","author":"Tarasova","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101834_bib87","first-page":"88","article-title":"Successful treatment of tumor-induced osteomalacia by multidisciplinary therapy with radiation to intracranial fibromyxoid tumor","volume":"8841259","author":"Massaccesi","year":"2021","journal-title":"Case Rep Endocrinol"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23001082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23001082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:00:36Z","timestamp":1761498036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X23001082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1521690X23001082"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2023.101834","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-induced osteomalacia: An overview","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2023.101834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101834"}}